T-Cypher Bio is an early-stage biotechnology company. T-Cypher Bio we believe that TCR-based therapeutics have the potential to transform the treatment of solid tumors, as well as autoimmune, inflammatory, and infectious diseases. Yet challenges in the identification of therapeutically relevant targets and TCRs have limited the application of suchtherapies.T-Cypher’s integrated platform, D-Cypher, overcomes these challenges.

Biotechnology

T-Cypher Bio

Thomas L. Andresen

Sarah Leonard

Nathaniel Davies

Mark Lees

Hemza Ghadbane

The Research and Development team at T-Cypher Bio focuses on advancing the company’s innovative TCR-based therapeutic platform, D-Cypher. Comprising experienced scientists and researchers, the team conducts cutting-edge studies to identify and validate therapeutically relevant targets and TCRs for solid tumors and various diseases. Their work is essential in transforming scientific discoveries into effective treatments, driving the company's mission to revolutionize biomedical therapy.

Research and Development

About

Team members

Other teams at T-Cypher Bio

Leadership Team